These preclinical results indicate that DNA damaging agents are effective and could be particularly useful in the treatment of PALB2-, BRCA1- or BRCA2- deficient pancreatic tumors, which is reminiscent of human cancers defective for ‘BRCAness’ [62, 63]. Here, BRCA2 is linked to pancreatic neoplasm.